Deal Watch: Merger Addresses Problems Of Both Aegerion, QLT

Convinced on safety, Shire buys Phase III-ready IBD candidate from Pfizer. Teva looks ahead to its acquisition of Allergan's generic portfolios by divesting ANDAs through two deals, while ending a stem cell collaboration with Mesoblast.